

insurance issuers. Nominations should be sent to the email or mailing address listed below. Acknowledgement of submissions will be provided within a week of submission.

**DATES:** Letters of nomination and résumés should be submitted no later than May 13, 2020, to ensure adequate opportunity for review and consideration of nominees prior to appointment.

**ADDRESSES:** Submit letters of nomination and résumés by either of the following methods:

Email: [PCORI@gao.gov](mailto:PCORI@gao.gov). Include PCORI Nominations in the subject line of the message, or Mail: U.S. GAO, Attn: PCORI Nominations, 441 G Street NW, Washington, DC 20548.

**FOR FURTHER INFORMATION CONTACT:** Ray Sendejas at (202) 512-7113 or [sendejasr@gao.gov](mailto:sendejasr@gao.gov) if you do not receive an acknowledgement or need additional information. For general information, contact GAO's Office of Public Affairs, (202) 512-4800.

**Authority:** Sec. 6301 and Sec. 10602, Pub. L. 111-148, 124 Stat. 119, 727, 1005 (2010); Div. N, Sec. 104, Pub. L. 116-94, 133 Stat. 2534 (2019).

**Gene L. Dodaro,**

*Comptroller General of the United States.*

[FR Doc. 2020-06313 Filed 3-31-20; 8:45 am]

**BILLING CODE 1610-02-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

**Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP) GH20-001, Develop, Implement, and Evaluate Evidence-Based, Innovative Approaches To Prevent, Find, and Cure Tuberculosis in High-Burden Settings; GH20-002, Malaria Operations Research To Improve Malaria Control and Reduce Morbidity and Mortality in Western Kenya; GH20-003, Conducting Public Health Research in Colombia; GH20-004, Conducting Public Health Research in Georgia; and GH20-005, Conducting Public Health Research in South America; Amended Notice of Meeting**

Notice is hereby given of a change in the meeting of the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—GH20-001, Develop, Implement, and Evaluate Evidence-Based, Innovative Approaches to Prevent, Find, and Cure Tuberculosis in High-Burden Settings; GH20-002,

Malaria Operations Research to Improve Malaria Control and Reduce Morbidity and Mortality in Western Kenya; GH20-003, Conducting Public Health Research in Colombia; GH20-004, Conducting Public Health Research in Georgia; and GH20-005, Conducting Public Health Research in South America; April 14-16, 2020, 9:00 a.m.–2:00 p.m., EDT, in the original FRN.

Teleconference, which was published in the **Federal Register** on March 16, 2020, Vol. 85, No. 51, page 14946.

The meeting is being amended to change the meeting dates and times to: April 14-15, 2020, from 9:00 a.m.–2:00 p.m., EDT; and April 16, 2020, from 9:30 a.m.–2:30 p.m., EDT. The meeting is closed to the public.

**FOR FURTHER INFORMATION CONTACT:** Hylan Shoob, Ph.D., Scientific Review Officer, Center for Global Health, CDC, 1600 Clifton Road NE, Atlanta, Georgia 30329-4027, Telephone (404) 639-4796; [HShoob@cdc.gov](mailto:HShoob@cdc.gov).

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2020-06780 Filed 3-31-20; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

**Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—TS-20-001, Identify and Evaluate Potential Risk Factors for Amyotrophic Lateral Sclerosis; Amended Notice of Meeting**

Notice is hereby given of a change in the meeting of the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—RFA-TS-20-001, Identify and Evaluate Potential Risk Factors for Amyotrophic Lateral Sclerosis; May 13, 2020, 1:00 p.m.–5:30 p.m., EDT, in the original FRN.

Teleconference, Centers for Disease Control and Prevention, 4770 Buford Highway NE, Atlanta, Georgia 30341,

which was published in the **Federal Register** on March 4, 2020, Volume 85, Number 43, pages 12786–12787.

The meeting is being amended to a virtual meeting with a meeting time of 9:30 a.m.–5:30 p.m., EDT. The meeting is closed to the public.

**FOR FURTHER INFORMATION CONTACT:**

Kimberly Leeks, Ph.D., M.P.H., Scientific Review Official, NCIPC, CDC, 4770 Buford Highway NE, Building 106, MS S106-9, Atlanta, Georgia 30341, telephone: (770) 488-6562; [KLeeks@cdc.gov](mailto:KLeeks@cdc.gov).

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2020-06781 Filed 3-31-20; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Medicare & Medicaid Services

[CMS-3389-FN]

**Medicare Program; Approval of Application by the Utilization Review Accreditation Commission for Initial CMS-Approval of Its Home Infusion Therapy Accreditation Program**

**AGENCY:** Centers for Medicare and Medicaid Services, HHS.

**ACTION:** Final notice.

**SUMMARY:** This final notice announces our decision to approve the Utilization Review Accreditation Commission (URAC) for initial recognition as a national accrediting organization for home infusion therapy suppliers that wish to participate in the Medicare program. A home infusion therapy supplier that participates must meet the Medicare conditions for coverage (CfCs).

**DATES:** The approval announced in this final notice is effective March 27, 2020 through March 27, 2024.

**FOR FURTHER INFORMATION CONTACT:**

Christina Mister-Ward, (410)786-2441. Lillian Williams, (410)786-8636.